NOTICIA
10/6/2026Resumen IA
GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
GSK acquires Nuvalent for $10.6B to bolster oncology pipeline with late-stage lung cancer treatments, aiming to offset future revenue drop from losing HIV medicine exclusivity.
C
CNBC4 min de lectura